血必净注射液治疗脓毒症的药理作用机制研究进展  

Research progress on pharmacological mechanism of Xuebijing Injection in treatment of sepsis

作　　者：李陆军[1] 马蓉 曹越 LI Lujun1, MA Rong2, CAO Yue2(1. First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China 2. Sale Company of Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Tianjin 300193, China)

机构地区：[1]黑龙江中医药大学附属第一医院,黑龙江哈尔滨150040 [2]天津中新药业集团股份有限公司销售公司,天津300193 [3]陕西中医药大学,陕西咸阳712046

出　　处：《药物评价研究》2018年第8期1548-1553,共6页Drug Evaluation Research

摘　　要：脓毒症是由于感染而引起的全身炎症反应综合征。血必净注射液是基于"菌毒炎并治"理念创制的中药复方制剂,与其他药物联合应用,在临床上治疗脓毒症效果确切。综述血必净注射液治疗脓毒症药理作用机制的研究进展,包括蛋白家族(如高迁移率族蛋白、中性粒细胞翻译控制肿瘤蛋白、肌红蛋白等)、细胞因子(炎性因子、血管内皮因子)和生物酶类(基质金属蛋白酶-9、诱导型一氧化氮合酶),以期更好地应用该药提供依据。Sepsis is a response syndrome caused by infection and systemic inflammatory. Xuebijing Injection is a Chinese materia medica compound formula which is based on ＂the principle of bacterial infection and treatment＂. It is used in combination with other drugs to treat sepsis with its definite effect. This review summarizes the research progress of pharmacological mechanism of Xuebijing Injection in the treatment of sepsis, such as protein family（high mobility group box protein, neutrophil translation controls tumor proteins, MYO）, cell factor（inflammatory factor, vascular endothelial growth factor）, and biological enzymes（MMP-9, i NOS）, in order to provide a basis for better application of this medicine.

关 键 词：血必净注射液 脓毒症 细胞因子 基质金属蛋白酶-9 

分 类 号：R285[医药卫生—中药学]